Home » Stocks » Radius Health

Radius Health, Inc. (RDUS)

Stock Price: $11.49 USD -0.61 (-5.04%)
Updated Aug 14, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 533.97M
Revenue (ttm) 200.47M
Net Income (ttm) -136.29M
Shares Out 46.47M
EPS (ttm) -2.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $11.49
Previous Close $12.10
Change ($) -0.61
Change (%) -5.04%
Day's Open 12.09
Day's Range 11.36 - 12.09
Day's Volume 854,833
52-Week Range 10.32 - 29.97

More Stats

Market Cap 533.97M
Enterprise Value 628.71M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 46.47M
Float 46.37M
EPS (basic) -2.94
EPS (diluted) -2.95
FCF / Share -1.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.56M
Short Ratio 11.33
Short % of Float 21.63%
Beta 1.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.66
PB Ratio n/a
Revenue 200.47M
Operating Income -112.99M
Net Income -136.29M
Free Cash Flow -74.77M
Net Cash -94.74M
Net Cash / Share -2.04
Gross Margin 78.83%
Operating Margin -56.36%
Profit Margin -68.00%
FCF Margin -37.30%
ROA -33.68%
ROE -421.96%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 2
Overweight 0
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$20.71*
(80.24% upside)
Low
14.0
Current: $11.49
High
28.0
Target: 20.71
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue17399.2422.11------
Revenue Growth74.65%348.8%-------
Gross Profit15790.8120.78------
Operating Income-112-204-249-185-99.08-59.39-67.37-64.43-41.51
Net Income-133-221-254-183-102-62.48-60.69-69.13-42.48
Shares Outstanding46.0345.3643.8043.0739.6417.700.380.370.22
Earnings Per Share-2.89-4.88-5.80-4.24-2.56-4.04-203.91-225.710.06
Operating Cash Flow-82.41-205-207-140-87.10-48.35-45.02-43.16-35.90
Capital Expenditures--0.19-2.34-2.94-1.23-0.86--0.04-0.18
Free Cash Flow-82.41-205-209-143-88.33-49.20-45.02-43.20-36.07
Cash & Equivalents16123725333247310512.3022.650.00
Total Debt202180166--24.3913.0120.81-
Net Cash / Debt-40.9057.2287.3333247380.88-0.701.850.00
Assets21928746234048210812.7625.30-
Liabilities26122622033.1021.1844.95290226-
Book Value-42.2860.6324230746163.46-277-201-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Radius Health, Inc.
Country United States
Employees 383
CEO George Kelly Martin

Stock Information

Ticker Symbol RDUS
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: RDUS
IPO Date June 6, 2014

Description

Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; Guardant Health, Inc.; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.